News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Danish biotech Bavarian Nordic has signed a $9m contract from Johnson & Johnson to improve stability of their joint Ebola vaccine. After options and milestone awards, payment could total $33m.
Baxalta will sell a Minnesota facility it acquired from Genmab in 2013 as part of a new outsourcing strategy it has adopted for biosimilar production.
MedImmune has first dibs on candidate cancer biologics identified at a lab the AstraZeneca unit set up with Cancer Research UK last week.